AstraZeneca rejects Pfizer’s final takeover bid
This is the fourth proposal Pfizer has made and it believes that the final proposal provides a clear basis for AstraZeneca to extend the period for making a
This is the fourth proposal Pfizer has made and it believes that the final proposal provides a clear basis for AstraZeneca to extend the period for making a
Pirfenidone, an orally active, anti-fibrotic agent, is an investigational therapy in the US and has not been approved by the US Food and Drug Administration (FDA). It inhibits
The submission is expected to take place in the third quarter of 2014 based on discussions with the FDA regarding the final results of PALOMA-1, a randomized, Phase
The open-label trial involved 12 CIS patients recruited from sites in the US to examine the efficacy of Vesimune over six doses. The trial population included both BCG
Candesartan ASKA is an authorized generic (AG) of Blopress (candesartan cilexetil), which Takeda has licensed the patent to Aska. Aska had received approval for the drug from the
ELIGARD (leuprolide acetate for injectable suspension) is designed to reduce the amount of testosterone in the body by reducing its production. The company said that it is not
Under the deal, Reckitt will be granted exclusive worldwide rights for the development and commercialization of XenoPort’s arbaclofen placarbil for all indications. Arbaclofen placarbil is a patent protected
The supply and distribution agreement was first agreed to by the companies in November 2010 and is due to expire on 31 December 2014. As part of the
The company will provide its lead cell permeable peptide targeting inflammatory diseases to Dr. Robert Nussenblatt to investigate its efficacy in animal models of uveitis. Portage will also
The company also secured final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for